| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return | vs S&P 500 ⓘ |
|---|---|---|---|---|---|---|
|
UPB
Upstream Bio, Inc.
|
Aug 11, 2026 | BUY |
Strong Buy
+435.7% avg upside
9 analysts
|
— | · | · |
|
ZURA
Zura Bio
|
Aug 11, 2026 | BUY |
Strong Buy
+160.2% avg upside
13 analysts
|
— | +0.0% | · |
|
GMAB
Genmab
|
Aug 11, 2026 | BUY |
Buy
+16.4% avg upside
27 analysts
|
— | +1.8% | · |
|
AUTL
Autolus Therapeutics
|
Aug 11, 2026 | BUY |
Strong Buy
+358.9% avg upside
16 analysts
|
— | -9.0% | · |
|
TENX
Tenax Therapeutics
|
Aug 10, 2026 | HOLD |
Strong Buy
+1504.9% avg upside
9 analysts
|
— | +24.6% | · |
|
JBIO
Jade Biosciences
|
Aug 10, 2026 | BUY |
Strong Buy
+155.3% avg upside
16 analysts
|
— | +6.8% | · |
|
JANX
Janux Therapeutics Inc
|
Aug 07, 2026 | BUY |
Strong Buy
+181.3% avg upside
21 analysts
|
— | +0.0% | · |
|
EVMN
Evommune, Inc.
|
Aug 07, 2026 | HOLD |
Strong Buy
+168.9% avg upside
12 analysts
|
— | +0.9% | · |
|
CMPX
Compass Therapeutics
|
Aug 07, 2026 | BUY |
Strong Buy
+323.8% avg upside
20 analysts
|
— | +2.3% | · |
|
XNCR
Xencor
|
Aug 06, 2026 | BUY |
Strong Buy
+56.5% avg upside
27 analysts
|
— | +13.8% | · |
|
CLYM
Climb Bio
|
Aug 06, 2026 | BUY |
Strong Buy
+38.1% avg upside
19 analysts
|
— | -2.8% | · |
|
CNTX
Context Therapeutics
|
Aug 06, 2026 | BUY |
Strong Buy
+1023.6% avg upside
12 analysts
|
— | -6.0% | · |
|
NAMS
NewAmsterdam Pharma Company
|
Aug 06, 2026 | BUY |
Strong Buy
+71.5% avg upside
19 analysts
|
— | +1.1% | · |
|
CGEM
Cullinan Management
|
Aug 06, 2026 | BUY |
Strong Buy
+73.8% avg upside
15 analysts
|
— | +9.0% | · |
|
INSM
Insmed
|
Aug 06, 2026 | BUY |
Strong Buy
+33.2% avg upside
37 analysts
|
— | -0.2% | · |
|
IMA
ImageneBio
|
Aug 05, 2026 | BUY |
Buy
+199.0% avg upside
12 analysts
|
— | -2.4% | · |
|
AMGN
Amgen
|
Aug 05, 2026 | BUY |
Buy
-23.9% avg upside
57 analysts
|
— | +2.3% | · |
|
KROS
Keros Therapeutics
|
Aug 04, 2026 | HOLD |
Strong Buy
+124.6% avg upside
21 analysts
|
— | +9.3% | · |
|
BMY
Bristol-Myers Squibb
|
Aug 03, 2026 | HOLD |
Buy
-4.4% avg upside
42 analysts
|
— | -1.0% | · |
|
ABBV
AbbVie
|
Jul 31, 2026 | BUY |
Strong Buy
-4.3% avg upside
46 analysts
|
— | -0.9% | · |
|
INCY
Incyte
|
Jul 28, 2026 | HOLD |
Buy
-11.2% avg upside
47 analysts
|
— | -7.1% | · |
|
ARGX
Argenx Se
|
Jul 27, 2026 | BUY |
Strong Buy
-9.3% avg upside
47 analysts
|
— | -1.4% | · |
|
JSPR
Jasper Therapeutics
|
Jun 01, 2026 | HOLD |
Strong Buy
+3201.3% avg upside
18 analysts
|
— | +54.3% | · |
|
AXSM
Axsome Therapeutics
|
Jan 03, 2026 | BUY |
Strong Buy
+8.8% avg upside
29 analysts
|
— | +25.2% | · |
|
IONS
Ionis Pharmaceuticals
|
Oct 11, 2025 | BUY |
Strong Buy
+42.3% avg upside
43 analysts
|
$116.76
110.69% Upside
|
-19.3% | · |
|
DNTH
Dianthus Therapeutics
|
Sep 13, 2025 | BUY |
Strong Buy
-10.4% avg upside
29 analysts
|
— | +203.5% | · |
|
INKT
MiNK Therapeutics
|
Aug 29, 2025 | HOLD |
Strong Buy
+96.1% avg upside
6 analysts
|
— | -20.2% | · |
|
AGEN
Agenus
|
Aug 29, 2025 | HOLD |
Strong Buy
+29.8% avg upside
18 analysts
|
— | +66.5% | · |
|
VRTX
Vertex Pharmaceuticals
|
Jun 28, 2025 | BUY |
Strong Buy
-15.5% avg upside
62 analysts
|
— | +10.4% | · |
|
MRNA
Moderna
|
Jun 07, 2025 | HOLD |
Hold
+17.8% avg upside
38 analysts
|
— | +68.6% | · |
|
TPST
Tempest Therapeutics
|
Apr 25, 2025 | HOLD |
Buy
+1775.0% avg upside
18 analysts
|
— | -76.9% | · |
|
NCNA
Nucana
|
Apr 25, 2025 | HOLD |
Buy
+789.8% avg upside
9 analysts
|
— | · | · |
|
IMUX
Immunic
|
Mar 29, 2025 | BUY |
Strong Buy
+158.7% avg upside
21 analysts
|
$1.20
92.19% Downside
|
+0.0% | · |
|
RNTX
Rein Therapeutics
|
Dec 29, 2022 | HOLD |
Strong Buy
+1017.9% avg upside
6 analysts
|
— | +63.1% | · |
|
PVLA
Palvella Therapeutics
|
Jan 03, 2022 | BUY |
Strong Buy
+9.4% avg upside
27 analysts
|
— | -72.1% | · |
|
ATRA
Atara Biotherapeutics
|
Dec 07, 2021 | BUY |
Buy
+105.0% avg upside
18 analysts
|
— | · | · |
|
ATNM
Actinium Pharmaceuticals
|
Nov 19, 2021 | BUY |
Strong Buy
+854.2% avg upside
11 analysts
|
— | +56.6% | · |
|
BIIB
Biogen
|
Jul 23, 2021 | BUY |
Strong Buy
+23.5% avg upside
52 analysts
|
— | -36.6% | · |
|
NKTR
Nektar Therapeutics
|
Jun 11, 2021 | BUY |
Buy
-0.4% avg upside
26 analysts
|
— | -81.2% | · |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.